Trastuzumab imbotolimod
- Generic Name
- Trastuzumab imbotolimod
Trial of BDC-1001 +/- Pertuzumab in Subjects with HER2-Positive Metastatic Breast Cancer
Phase 2
Terminated
- Conditions
- Metastatic Breast CancerHER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Bolt Biotherapeutics, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT05954143
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Virginia Cancer Specialists, Arlington, Virginia, United States
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
A First-in-human Study Using BDC-1001 As a Single Agent and in Combination with Nivolumab in Advanced HER2-Expressing Solid Tumors
Phase 1
Terminated
- Conditions
- HER2-positive Colorectal CancerHER2-positive Solid TumorsHER2-positive Endometrial CancerHER2-positive Breast CancerHER2-positive Gastroesophageal Cancer
- Interventions
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Bolt Biotherapeutics, Inc.
- Target Recruit Count
- 175
- Registration Number
- NCT04278144
- Locations
- 🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath